Marilyne Poiree
Overview
Explore the profile of Marilyne Poiree including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo C, Mornet C, Storey C, Halfon-Domenech C, Pochon C, Tabone M, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40033132
No abstract available.
2.
Domenech C, Kicinski M, De Moerloose B, Piette C, Chahla W, Kornreich L, et al.
Hemasphere
. 2024 Nov;
8(11):e70025.
PMID: 39540141
Here, we report the results of the prospective cohort study EORTC-CLG 58081 and compare them to the control arm of the randomized phase 3 trial EORTC-CLG 58951, on which treatment...
3.
Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, et al.
Eur J Cancer
. 2024 Nov;
213():115073.
PMID: 39509848
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements...
4.
Poiree M, Gofti-Laroche L, Riberon C, Leblond P, Laurence V, Gaspar N, et al.
J Adolesc Young Adult Oncol
. 2024 Sep;
PMID: 39324243
The "Groupe Onco-hématologie Adolescents Jeunes Adultes" (GO-AJA) born in 2012 is a French collaborative group. It focuses on heterogeneity and unmet needs for AYA with cancer. This article highlights GO-AJA's...
5.
Renaux Torres M, Bouttefroy S, Letort-Bertrand M, Maurel V, Mouffak S, Scotte F, et al.
Bull Cancer
. 2024 Apr;
111(6):608-619.
PMID: 38670821
Chemotherapy-induced nausea and vomiting (CINV) are frequent and dreaded side effects in cancer treatments. CINV has a major impact on patient's condition and quality of life. Prophylaxis is tailored to...
6.
Ducassou S, Abou Chahla W, Duployez N, Halfon-Domenech C, Brethon B, Poiree M, et al.
Bull Cancer
. 2024 Mar;
111(5):513-524.
PMID: 38503585
Neonatal acute myeloid leukemias (AML) occurred within the first 28 days of life and constitute only a small proportion of all AL. They are distinguished from leukemias of older children...
7.
Huault A, Michel G, Charon V, Chouklati K, Domenech C, Chastagner P, et al.
Pediatr Hematol Oncol
. 2023 Feb;
40(5):458-474.
PMID: 36820621
Osteonecrosis (ON) is a known complication of acute leukemia (AL) management, affecting 1%-10% of young patients and resulting in long-term morbidity. Widespread access to MRI over the past decade has...
8.
Thouvenin-Doulet S, Mouffak S, Bertrand A, Cardine A, Letort-Bertrand M, Levy D, et al.
Bull Cancer
. 2022 Oct;
109(11):1144-1153.
PMID: 36220696
Nausea and vomiting induced by cancer treatment (CINV) remain one of the most common and feared side effects in children despite the use of new drugs to prevent them. The...
9.
Poiree M, Neumann F, Thomas C, Simon P, Lunven A, Plantaz D, et al.
Bull Cancer
. 2022 Aug;
109(11):1125-1131.
PMID: 35987855
Pegaspargase (Oncaspar®), a pegylated form of native Escherichia Coli-derived L-asparaginase is an essential component chemotherapy used in the treatment of acute lymphoblastic leukemia (ALL) in pediatric and adult patients. Its...
10.
Le Louet S, Icart V, Strullu M, Petit A, Freycon C, Blouin P, et al.
J Cancer
. 2022 Mar;
13(4):1272-1281.
PMID: 35281861
Ten to fifteen percent of children with acute lymphoblastic leukemia (ALL) relapse following treatment. Of these, less than 2% display ophthalmic relapses, which owing to their scarcity, are largely undocumented,...